{"filings":[{"id":121925,"accession_number":"0001104659-25-123187","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Shareholders approve equity plan increase and dilutive share issuance at TAO Synergies annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Equity plan amended to increase authorized shares by 500,000 to 3,175,000; approved with 994,315 votes for.","Proposal to authorize issuance of common stock underlying convertible preferred and warrants (≥20% of outstanding) passed with 504,481 for.","Bruce T. Bernstein elected to board until 2028 with 1,040,943 votes for; quorum of 43.18% (3,318,341 shares).","Stephano Slack LLC ratified as auditor for FY2025 with 3,241,023 votes for.","Adjournment proposal approved to allow further solicitation if needed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121924,"accession_number":"0001104659-25-098909","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","3.02","7.01","8.01","9.01"],"status":"ready","headline":"TAO Synergies raises $11M in private placement; terminates Alkon agreement; appoints Vice-Chairman","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Sold 11,000 Series E convertible preferred shares ($1,000 stated value) and warrants for 1.375M common shares at $8.00; $11M gross proceeds.","Investors include existing stockholders, James Altucher, and new strategic investor DCG; expected close Oct 15.","Proceeds for general corporate purposes and working capital, focusing on Bittensor (TAO) ecosystem investments.","Terminated consulting agreement with Dr. Daniel Alkon effective Oct 3; remains liable for incentive fees on Bryostatin transactions for one year.","Appointed Bruce Bernstein as Vice-Chairman of the Board effective Oct 1; William Singer remains independent director."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138619,"accession_number":"0001104659-25-085770","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["5.02","7.01","8.01","9.01"],"status":"ready","headline":"TAO Synergies appoints Joseph Jacks as advisor for Bittensor treasury strategy; board adds Robert Ephron","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Joseph Jacks, co-founder/CEO of Latent Holdings and early Bittensor pioneer, engaged as advisor to digital asset treasury strategy led by James Altucher.","Consulting agreement grants warrants for 100,000 shares at $8.40 per share, expiring in 5 years.","Jonathan Schechter and Dr. Alan Tuchman resigned from board (Tuchman remains CMO); no disagreement cited.","Robert Ephron appointed to board, serving on audit, compensation and nominating committees; waived initial option grant.","Jacks' OSS Capital led over 40 seed-stage rounds totaling $200M+; his Latent Holdings stewards key Bittensor subnet repositories."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138618,"accession_number":"0001104659-25-075748","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2025-08-08T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"TAOX shareholders approve 20%+ share issuance and 2M-share equity plan increase","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Aug 6, 2025; 567,847 shares (35.23%) represented, quorum achieved.","Proposal 1 approved issuance of common stock >20% of outstanding (from convertible preferred & warrants); 500,450 for, 66,872 against.","Proposal 2 approved amendment to 2020 Equity Incentive Plan, increasing shares reserved by 2,000,000 to 2,675,000; 492,781 for, 73,988 against.","Proposal 3 (adjournment) also passed; 523,728 for, 42,865 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138617,"accession_number":"0001104659-25-074544","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"TAO Synergies accumulates 42,111 Bittensor (TAO) tokens as part of DeAI treasury strategy","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["As of Aug 5, 2025, holds 42,111 TAO tokens acquired via purchases and staking.","Claims to be world's largest publicly traded pure-play Bittensor treasury company.","Strategy focuses on intersection of decentralized AI and blockchain.","Actively staking on the Bittensor (TAO) network to earn additional tokens.","Accumulation achieved in only two months since launching TAO-focused strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138616,"accession_number":"0001104659-25-068559","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2025-07-17T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"TAO Synergies acquires $10M in TAO tokens, becoming largest public pure play holder","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquired 29,899 TAO tokens for $10M at avg ~$334/token as of July 17, 2025.","Claims position as largest publicly traded pure play TAO holder worldwide.","Stakes tokens in Bittensor decentralized AI network for yield generation.","Executive Chairman cites attractive entry point and conviction in decentralized AI growth.","Digital asset treasury strategy continues; further TAO purchases planned."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156078,"accession_number":"0001104659-25-063601","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2025-06-27T23:59:59+00:00","items":["5.02","5.03","7.01","9.01"],"status":"ready","headline":"Synaptogenix rebrands to TAO Synergies, shifts to AI-focused crypto treasury with staking","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name changed to TAO Synergies Inc. effective June 26, 2025; ticker to change from SNPX to TAOX on July 1.","CEO Alan Tuchman resigned June 8, remains as director and Chief Medical Officer; salary cut to $7,500/month.","New strategy focuses on AI token TAO as cornerstone of digital asset treasury; staking TAO to generate revenue.","No stockholder vote required for name change; CUSIP unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156077,"accession_number":"0001104659-25-062128","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2025-06-24T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Synaptogenix buys TAO, hires BitGo for custody/staking, begins staking yield","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Initial purchase of TAO under crypto treasury strategy focused on AI and machine learning.","BitGo selected as qualified custodian; TAO held in insured cold storage with BitGo Trust.","TAO staking has begun, generating revenue for the Company.","Acquisition funded by cash reserves; no external financing used.","James Altucher leads Crypto TAO strategy; Board cites long-term conviction in TAO."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":156076,"accession_number":"0001104659-25-057640","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2025-06-09T23:59:59+00:00","items":["1.01","3.02","5.02","7.01","9.01"],"status":"ready","headline":"Synaptogenix launches crypto treasury strategy focused on Bittensor TAO, raises $5.5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Plans initial $10M acquisition of TAO tokens (over 2x market cap); long-term target of $100M.","Raised $5.5M via private placement of Series D convertible preferred stock ($1,000 stated value) and warrants at $3.00 per share.","James Altucher hired as consultant to lead TAO strategy; issued 1.2M warrants with exercise prices from $4.00 to $12.00.","CEO Dr. Tuchman resigned to become CMO; CSO Dr. Alkon resigned to consultant; Joshua Silverman appointed Executive Chairman at $30k/month.","Company intends to change name and ticker to reflect new digital asset treasury strategy."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191486,"accession_number":"0001104659-24-130537","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2024-12-20T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"Synaptogenix forms special committee to explore strategic alternatives; ends Bryostatin-1 MS trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board formed special committee to explore strategic opportunities; $19.6M cash and ~1.3M shares outstanding as of Sept 30, 2024.","Terminated Phase 1 trial of Bryostatin-1 in multiple sclerosis due to slow enrollment.","CEO Alan Tuchman's base salary reduced to $12,500/month effective Jan 1, 2025.","President/CSO Daniel Alkon consulting fee reduced to $16,000/month under new agreement.","Company expects dramatic cash burn decline; submitted NIH grant proposal for Bryostatin-1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191485,"accession_number":"0001104659-24-126355","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Synaptogenix shareholders approve stock issuance authorization and equity plan increase at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected directors Silverman (369,569 for) and Singer (367,990 for); broker non-votes 368,218.","Authorized board to issue shares >20% of outstanding under Sept 10, 2024 purchase agreement; 246,470 for, 100,776 against.","Approved amendment to 2020 Equity Plan raising authorized shares from 175,000 to 675,000; 270,829 for, 194,623 against.","Ratified Stephano Slack as auditor for FY2024; 690,006 for, 143,414 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":191484,"accession_number":"0001104659-24-106284","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2024-10-04T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Synaptogenix replaces auditor: Morison Cogen resigns, Stephano Slack engaged for FY2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Morison Cogen resigned Sept 30, 2024 due to exit from public company audit services.","Prior years' reports (2022, 2023) were unqualified; no disagreements or reportable events.","New auditor Stephano Slack engaged Oct 4 for FY2024 audit.","No prior consultations with Stephano Slack on disputed or reportable accounting matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207964,"accession_number":"0001104659-24-099847","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2024-09-13T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Synaptogenix raises $5M via Series C Convertible Preferred and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of Series C Preferred (convertible at $4/share) and warrants for aggregate gross proceeds of $5M.","Preferred carries 5% annual cash dividend, 107% quarterly amortization redemption starting Oct 31, 2024.","Company must seek stockholder approval by Dec 31, 2024 to issue more than 19.99% of common stock upon conversion.","Holders can force cash redemption after first anniversary; Triggering Events include failure to register shares.","Covenants restrict indebtedness, liens, acquisitions, dividends, and asset transfers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207963,"accession_number":"0001104659-24-098800","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2024-09-11T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Synaptogenix raises $5.0M via Series C preferred stock and warrants, convertible/exercisable at $4.00/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $5.0M from sale of 5,000 shares of Series C convertible preferred stock (stated value $1,000) and warrants.","Series C convertible at $4.00/share, pays 5% quarterly cash dividend; warrants exercisable at $4.00 for 5 years.","Closing expected September 12, 2024; net proceeds for general corporate purposes, including potential R&D or acquisitions.","CEO Alan Tuchman noted support from existing investors and aims to be strategic for growth and shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207962,"accession_number":"0001104659-24-098197","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2024-09-09T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Synaptogenix extends Series B Preferred maturity date to Sept 9, 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment to Series B Convertible Preferred Stock on Sept 3, 2024.","Maturity date extended from August 31, 2024 to September 9, 2024.","Further extensions permitted under Certificate of Designations."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225480,"accession_number":"0001104659-24-073915","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Synaptogenix extends CEO Alan J. Tuchman's employment through Dec 7, 2024 with automatic monthly renewals","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Amendment No. 3 to Offer Letter extends CEO term to December 7, 2024.","Term automatically renews monthly unless either party gives 7-day written notice.","Company may terminate employment on 7 days' written notice.","Amendment adds Section 409A compliance and Section 280G excise tax reduction provisions.","No other changes to compensation or existing terms; Offer Letter remains in effect."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":225479,"accession_number":"0001104659-24-043683","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2024-04-04T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Synaptogenix effects 1-for-25 reverse stock split to regain Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split effective 5pm ET April 4, 2024; shares trade split-adjusted on April 5 under SNPX.","Every 25 pre-split shares converted into 1; no fractional shares; cash in lieu at closing price.","Shares outstanding reduced from ~27.1M to ~1.08M, subject to fractional adjustment.","Proportional adjustments to equity awards, convertible preferred, and warrants.","New CUSIP 87167T300; action needed for physical certificate holders only."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262083,"accession_number":"0001104659-23-128289","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2023-12-21T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Synaptogenix stockholders approve reverse stock split authorization and tripling of equity plan shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders authorized reverse stock split at ratio between 1:8 and 1:25, at Board's discretion.","Amendment to 2020 Equity Incentive Plan approved, increasing authorized shares from 1.375M to 4.375M.","Directors Alan Tuchman and Daniel L. Alkon elected with ~4.5M and ~4.7M for votes respectively.","Ratification of Marcum LLP as auditor for FY2023 approved with ~10.66M for votes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":262082,"accession_number":"0001104659-23-114810","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2023-11-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Synaptogenix invests up to ~$3.44M in Cannasoul Analytics for preferred shares and convertible notes","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Initial investment: $562,770 for 12,737 Series A preferred shares (5% stake) at $44.1550/share.","Initial convertible note of $1.44M; up to $2M in milestone notes subject to Cannasoul revenue/expense goals.","Synaptogenix gets 3 of 7 board seats, veto power on 4th, preemptive rights, and veto over major transactions.","Collaboration agreement to form joint research committee for cannabinoid compounds from Technion lab.","If Cannasoul misses milestones, investor loses board rights and preferred shares may be converted to ordinary shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279295,"accession_number":"0001104659-23-103184","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2023-09-22T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Synaptogenix amends Series B Preferred terms to allow stock-for-cash amortization by mutual agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Filed Certificate of Amendment on Sept. 22, 2023, modifying Series B Convertible Preferred Stock terms.","Company and holders may mutually agree to pay monthly amortization in cash or common stock during an Equity Conditions Failure.","Amendment also permits mutual agreement on true-up share calculation methodology and any premium for cash true-up payments.","Goal is to conserve cash by allowing stock payments instead of cash when equity conditions fail."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":279294,"accession_number":"0001104659-23-082211","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2023-07-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Synaptogenix partners with Cleveland Clinic for Phase 1 Bryostatin-1 trial in multiple sclerosis","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Agreement with Cleveland Clinic to conduct Phase 1 trial of Bryostatin-1 in multiple sclerosis; IND submission to FDA planned.","Trial expected to commence in Q4 2023 at Cleveland Clinic's Mellen Center for Multiple Sclerosis.","Synaptogenix had approximately $35.8M in cash as of March 31, 2023, sufficient to fund the trial and other developments.","Bryostatin-1 targets synaptic regeneration and anti-inflammatory pathways; cognitive impairment is a key unmet need in MS."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297662,"accession_number":"0001104659-23-073833","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2023-06-22T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Synaptogenix extends CEO Alan Tuchman's employment through June 7, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Alan Tuchman's employment term extended to June 7, 2024 with automatic monthly renewals.","Added Section 409A compliance provisions for deferred compensation.","Added Section 280G 'best net' reduction provision for potential excise tax.","No changes to other terms of the offer letter."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297661,"accession_number":"0001104659-23-053140","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2023-04-28T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Synaptogenix receives Nasdaq delisting notice for bid price below $1.00","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Synaptogenix on April 24, 2023 that its stock failed to maintain minimum $1.00 closing bid price for 30 consecutive days.","Company has a 180-day grace period, until October 23, 2023, to regain compliance; stock continues trading under SNPX.","Compliance can be achieved if closing bid price is at least $1.00 for 10 consecutive business days within the grace period.","If non-compliance continues after October 23, 2023, Synaptogenix may seek additional time by meeting other listing standards and notifying Nasdaq."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297660,"accession_number":"0001104659-23-045665","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2023-04-14T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Synaptogenix stockholders authorize issuance of shares underlying convertible preferred stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting on April 14, 2023; 2,923,975 shares (40.23%) represented, quorum present.","Vote to authorize issuance of common stock underlying convertible preferred stock and warrants from November 2022 SPA.","Approved with 2,077,004 for, 791,292 against, 55,679 abstentions.","Issuance could exceed 20% of outstanding common stock, required Nasdaq Listing Rule 5635(d) approval."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317935,"accession_number":"0001104659-23-029338","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2023-03-07T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"Synaptogenix cash balance ~$37.5M as of Dec. 31, 2022","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Cash and cash equivalents of approximately $37.5 million as of December 31, 2022.","Disclosed in a press release issued March 7, 2023.","No additional financial results or forward-looking statements provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317934,"accession_number":"0001104659-23-023328","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2023-02-17T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Synaptogenix special meeting adjourned without business, reconvene date TBD","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special meeting held Feb 16, 2023 was adjourned with no business conducted.","Meeting will reconvene at a date and time to be determined later.","Record date remains December 20, 2022; no proposals were voted on.","Chairman Joshua Silverman announced the adjournment at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336200,"accession_number":"0001104659-22-130531","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2022-12-28T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Synaptogenix reduces stockholder meeting quorum from majority to one-third","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board approved amendment to Bylaws, effective December 27, 2022.","Quorum reduced from majority to at least one-third of outstanding voting shares.","Amendment filed as Exhibit 3.1 to this report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336199,"accession_number":"0001104659-22-127597","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2022-12-16T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Synaptogenix Phase 2 trial of Bryostatin-1 fails to meet primary endpoint in advanced Alzheimer's","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: change in SIB total score at week 28; Bryostatin-1 1.4 pts vs placebo 0.6 pts, not statistically significant.","Company disappointed, conducting full data review; will provide update on next steps.","Cash position of ~$38.5M (~$4.00 per share) as of Dec 15, 2022, provides flexibility.","Trial was NIH-sponsored, double-blind, placebo-controlled for advanced Alzheimer's disease."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336198,"accession_number":"0001104659-22-121017","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2022-11-22T23:59:59+00:00","items":["5.03","8.01","9.01"],"status":"ready","headline":"Synaptogenix creates Series B Convertible Preferred, closes $15M private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued Series B Convertible Preferred Stock with initial conversion price of $7.75 per share.","Gross proceeds of $15 million from private placement of Preferred Shares and warrants.","Preferred Shares carry 7% annual dividend (15% on trigger events), payable in cash or common stock.","Mandatory redemption in 15 equal monthly installments starting April 1, 2023, payable in cash or stock.","Company must seek stockholder approval by March 1, 2023 to issue over 19.9% of outstanding common stock."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336197,"accession_number":"0001104659-22-120092","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2022-11-18T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Synaptogenix raises $15M from existing investors in private placement of preferred stock and warrants","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $15M from sale of Series B convertible preferred stock (initial conversion at $7.75/share) and warrants.","Warrants to acquire up to 1,935,485 shares at $7.75; 5-year term; conversion price ~25% premium to prior close.","Closing expected Nov 21, 2022; net proceeds for general corporate purposes.","CEO cites strengthening balance sheet ahead of topline Phase 2 Alzheimer's trial results expected in December 2022.","Preferred shares carry 7% annual dividend, redeemable in 15 monthly installments starting April 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":336196,"accession_number":"0001104659-22-108170","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2022-10-13T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve amendment to 2020 Equity Incentive Plan, doubling authorized shares to 1.375M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["At Oct 11 annual meeting, 56.32% of shares represented; all three proposals passed.","Plan amendment increased authorized shares from 625k to 1.375M (approved 1,079,386 for, 329,999 against).","Directors Bruce T. Bernstein and Jonathan L. Schechter elected to hold office until 2025.","Ratification of Morison Cogen LLP as independent auditor for FY2022 passed with 3,793,131 votes for."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353626,"accession_number":"0001104659-22-091784","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2022-08-16T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Synaptogenix dismisses Friedman LLP, appoints Morison Cogen as auditor effective Sept 1, 2022","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Audit committee elected not to continue with Friedman LLP as independent auditor effective Sept 1, 2022.","Morison Cogen LLP appointed as new independent registered public accounting firm commencing Sept 1, 2022.","Change due to Friedman's impending merger with Marcum LLP, which may create a conflict of interest.","No disagreements or reportable events between company and Friedman for 2020, 2021, or interim periods through June 2022.","Prior audit reports for 2020 and 2021 contained no adverse opinion or qualification."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":408342,"accession_number":"0001104659-21-122088","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2021-10-01T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"George Perry resigns from Synaptogenix board, retains advisory role","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Perry resigned from board and all committees effective September 30, 2021.","Resignation was voluntary and not due to any disagreement with company operations or policies.","Perry will continue to serve as Chairman of the Scientific Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":427315,"accession_number":"0001104659-21-093138","cik":1571934,"company_name":"TAO Synergies Inc.","ticker":"TAOX","form_type":"8-K","filed_at":"2021-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Synaptogenix grants 485,000 RSUs to directors and officers for spin-off and up-listing efforts","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["RSUs awarded to 8 individuals (including CEO, CFO, directors) totaling 485,000 shares.","Joshua N. Silverman (CEO) receives 90,000 RSUs; Dr. Daniel Alkon (Chief Scientific Officer) 80,000.","Vesting: 50% at 6-month anniversary, 50% at 1-year anniversary of July 13, 2021 grant date.","Grant rewards efforts on spin-off, Nasdaq up-listing, and June 2021 private placement financing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":32174133.37360179,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}